Dernières nouvelles pour Redhill Biopharma (NASDAQ:RDHL) Stock

Redhill Biopharma

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma Ltd

Gray Media, Inc. ("Gray" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTN#NYSE">GTN</a>) today announced that it has (i) increased the aggregate commitments under its revolving credit facility (the "Revolving Credit Facility") by $50 million, resulting in aggregate commitments under the Revolving Credit Facility of $750 million, and (ii) extended the maturity date of the Revolving Credit Facility from December 1, 2027 to December 1, 2028.&nbsp;
In connection with the amendment and the previously announced offering of $900 million aggregate principal amount of 9.625% senior secured second lien notes due 2032 (the "Notes"), there is $700 million of undrawn availability under the Revolving Credit Facility (excluding approximately $8 million of outstanding letters of credit). The Revolving Credit Facility is available on a revolving basis. The Company also repaid $402.5 million of its term loan F due June 4, 2029 (the "Term Loan F") with the net proceeds from the Notes, leaving an outstanding Term Loan F balance of $90 million and satisfying all of the Company's mandatory amortization payments prior to maturity.

News

Gray Media Expands Revolving Credit Facility To $750M And Extends Maturity To December 2028

<ul>
<li>Brookfield Renewable will invest up to $1 billion and increase its equity interest in Isagen to approximately 38%</li>
<li>As part of this transaction, QIA, an existing co-investor in Isagen, will invest approximately $500 million and increase its equity interest in Isagen to approximately 15%</li>
</ul>
Brookfield Renewable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEP#NYSE">BEP</a>, BEPC, TSX:<a class="ticker" href="https://www.benzinga.com/stock/BEP#TSX">BEP</a>, BEPC))) ("Brookfield Renewable") today has announced that it will invest up to $1 billion to increase its equity interest to approximately 38% in Isagen S.A. E.S.P. ("Isagen").
Isagen generates stable and contracted cash flows from its large fleet of hydro assets. The business owns and operates an essential asset base, enhancing the reliability of Colombia's power grid. In addition, Isagen also has a pipeline of renewable power projects, which we are well equipped to develop and bring into production to support Colombia's growing power needs.
This transaction re-affirms Brookfield Renewable's commitment to Colombia and will result in Brookfield Renewable's ownership interest in Isagen increasing to approximately 38%, growing the proportion of our cash flows from our hydro portfolio, an increasingly strategic part of our business given its scale, dispatchability, and baseload characteristics.
The transaction is expected to be immediately accretive to Brookfield Renewable's FFO per unit and is anticipated to be approximately 2% accretive to 2026 FFO per unit, on the back of strong cash flow visibility with ~70% of the platform's generation contracted for an average of eight years.
The investment will be funded through a combination of proceeds from non-recourse financings at the business and available liquidity. The transaction is expected to close in the third quarter.
As part of this transaction, Qatar Investment Authority ("QIA"), an existing co-investor in Isagen, will invest approximately $500 million and increase its equity interest in Isagen to approximately 15%. This investment aligns with QIA's commitment to invest in companies that support the global transition to a low-carbon future.

BEPC

TSX:BEP

Brookfield Renewable To Invest Up To $1B To Increase Its Equity Interest To ~38% In Isagen

A millennial started an interesting conversation on Reddit recently after asking a simple but loaded question: &#8220;Anyone else grow up rich and now totally isn&#8217;t?&#8221; The <a href="https://www.reddit.com/r/Millennials/comments/1lxj22v/anyone_else_grow_up_rich_and_now_totally_isnt/">post</a> really spoke to a lot of millennials who feel like life got a lot harder than it was for their parents.
<h2 class="wp-block-heading">Middle-Class Kids, Grown-Up Struggles</h2>
The original poster shared that while their family didn't take lavish international trips, they grew up in large houses, stayed in expensive hotels, and were surrounded by <a href="https://www.benzinga.com/personal-finance/24/10/41418853/people-think-generational-wealth-is-for-rich-people-only-says-shaquille-oneal-but-he-thinks-its-">generational wealth</a>. Now, at 34, they're living in a <a href="https://www.benzinga.com/markets/24/12/42417469/gen-x-and-the-housing-boom-24-of-buyers-you-cant-ignore">multi-generational home</a>, paying rent to in-laws, and see no shot at entering the housing market before their late 40s. &#8220;All this wealth just seemed so much easier back then,&#8221; they wrote.
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – Many are rushing to grab <a href="https://www.benzinga.com/money/mode-mobile-2">4,000 of its pre-IPO shares for just $0.30/share</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
Hundreds replied with similar experiences, describing how their childhoods were filled with stability, vacations, and private schools. Today, <a href="https://www.benzinga.com/personal-finance/management/25/05/45710917/whats-driving-americans-to-live-paycheck-to-paycheck-one-person-says-its-like-being-thrown-into-adulthood-without-a-map">many live paycheck to paycheck</a>, even with decent salaries. One commenter pointed out that they make about the same salary their dad did in the early 2000s. Back then, it bought a five-bedroom house, cars and vacations. Now they can barely cover rent with it.
&#8220;I work in public service and am grateful to afford a shack house in a bad neighborhood,&#8221; another millennial noted. &#8220;I am two paychecks away from <a href="https://www.benzinga.com/news/topics/25/07/46330308/are-you-really-free-if-your-groceries-are-so-expensive-you-cant-afford-them-asks-former-ftc-chair-lina-khan-challenging-corporate-power">being unable to afford necessities</a>.&#8221;
A recurring frustration was the generational gap in understanding. Several millennials said their parents often praise them for doing well, not realizing how drastically the value of money has changed. &#8220;My Mom keeps telling me that I am doing great, her mind is also skewed as she sees my salary as if it is the &#8217;90s,&#8221; one person wrote.
Trending: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a>
Some talked about going from international travel and country clubs to <a href="https://www.benzinga.com/content/44657977/grocery-costs-and-tariffs-now-top-of-mind-in-everyday-conversations-new-survey-finds">worrying about grocery bills</a>. One summed it up: &#8220;I knew I lived a charmed life, but I didn't know just how charmed until I became an adult.&#8221;
&#8220;I'll never have the life I grew up with, and it makes me feel like a failure,&#8221; one person said.
<h2 class="wp-block-heading">Gratitude And Grief</h2>
The emotional toll came through clearly. Some shared that they had good relationships with their families and even got occasional financial help. Others were estranged and completely on their own. &#8220;[My parents] still have it all,&#8221; OP later added. &#8220;I&#8217;m estranged.&#8221;
For some, the takeaway was less about money and more about perspective. &#8220;Once basic comforts are taken care of and you have some free time, the rest is window dressing,&#8221; one comment read. You&#8217;re happy or unhappy because of how your brain works and your relationships, not <a href="https://www.benzinga.com/personal-finance/25/05/45483330/are-you-rich-or-just-upper-middle-class-heres-the-net-worth-and-income-it-takes-to-be-considered-wealthy">your net worth</a>.
Read Next:&nbsp;
<ul class="wp-block-list">
<li>This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — <a href="https://www.benzinga.com/money/finally-a-fully-automated-trading-platform-for-individual-investors?">You Can Become an Investor for Just $500.25</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
</ul>
Image: Shutterstock

Personal Finance

A Millennial Asks, 'Anyone Else Grow Up Rich And Now Totally Isn't?' Says Being Wealthy 'Just Seemed So Much Easier Back Then'

Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) has outperformed the market over the past 5 years by 6.53% on an annualized basis producing an average annual return of 20.59%. Currently, Ferguson Enterprises has a market capitalization of $44.71 billion. 
Buying $100 In FERG: If an investor had bought $100 of FERG stock 5 years ago, it would be worth $255.05 today based on a price of $222.79 for FERG at the time of writing.
<h3>Ferguson Enterprises's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752870612_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

FERG

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

HOOK

Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times

Offerings

BRCC

BRC Files For Offering Of 28M Shares Of Class A Common Stock

The Special Committee of the Board of Directors of FONAR Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FONR#NASDAQ">FONR</a>) ("FONAR"), The Inventor of MR Scanning&#x2122;, today confirmed receipt of a supplemental proposal letter, dated July 17, 2025, from the Proposed Acquisition Group led by Timothy Damadian. The supplemental letter states that the Proposed Acquisition Group is contemplating the pursuit of a plan to acquire all of the outstanding shares capital stock of FONAR not currently owned by the Proposed Acquisition Group, at a price of $17.25 per share in cash. The letter states that the proposed share price represents a premium of approximately 27% over the average closing price of the Common Stock for the 90 trading day trading period ending on June 30, 2025. A copy of the Proposed Acquisition Group's supplemental letter is attached as an exhibit to the Group's Amended Schedule 13D/A No.1, which is available for review by the public on the Securities and Exchange Commission's website.
The Special Committee, composed of independent and disinterested directors, was formed in response to interest expressed by the Proposed Acquisition Group in exploring a possible transaction in a letter delivered to the FONAR Board and dated July 7, 2025. The Special Committee will carefully review the supplemental proposal in consultation with independent financial and legal advisors to determine the course of action that is in the best interest of FONAR and all shareholders. No action is required by FONAR shareholders at this time.
FONAR cautions its shareholders and others considering trading in FONAR's securities that FONAR has only recently received the supplemental proposal letter and no decisions have been made with respect to FONAR's response to the proposed transaction. The proposal constitutes only an indication of interest by the Proposed Acquisition Group and does not constitute a binding commitment.
There can be no assurance that any agreement will be executed or that the transaction contemplated in the proposal or any other transaction will be approved or consummated. No agreement, arrangement or understanding between FONAR and the Proposed Acquisition Group relating to any proposed transaction will be created unless definitive documentation is executed and delivered by the appropriate parties.
FONAR does not anticipate making any further public statements about this matter or the activities of the Special Committee unless and until either it enters into a definitive agreement for a transaction or the Special Committee determines that no such transaction will be effected.

FONR

FONAR Receives $17.25/Share Cash Buyout Proposal From Timothy Damadian-Led Group; Special Committee Will Carefully Review The Supplemental Proposal In Consultation With Independent Financial And Legal Advisors To Determine The Course Of Action That Is In The Best Interest Of Fonar And All Shareholders

VRAX

Virax Biolabs Received Nasdaq Noncompliance Letter

Management

ICMB

Investcorp Credit Management CFO Walter Tsin Resigns Effective July 16, 2025; Robert Muns Appointed As CFO

Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) has outperformed the market over the past 10 years by 4.11% on an annualized basis producing an average annual return of 15.67%. Currently, Texas Instruments has a market capitalization of $196.79 billion. 
Buying $100 In TXN: If an investor had bought $100 of TXN stock 10 years ago, it would be worth $439.39 today based on a price of $216.62 for TXN at the time of writing.
<h3>Texas Instruments's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752869721_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

<a href="https://www.sec.gov/Archives/edgar/data/1976908/000110465925069022/tm2521218d1_6k.htm" title="https://www.sec.gov/Archives/edgar/data/1976908/000110465925069022/tm2521218d1_6k.htm">https://www.sec.gov/Archives/edgar/data/1976908/000110465925069022/tm2521218d1_6k.htm</a>

JDZG

JIADE Regained Nasdaq Compliance

General

SDRL

On July 11, High Court Rules In Favor Of Claimant For Dispute Related To JV In Angola;  Judgment Impact On Adj EBITDA For FY Expected To Be $10M

Amcon Distributing (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/DIT#AMEX">DIT</a>) reported quarterly earnings of $2.13 per share. This is a 13.41 percent decrease over earnings of $2.46 per share from the same period last year. The company reported $739.615 million in sales this quarter. This is a 3.03 percent increase over sales of $717.852 million the same period last year.

Earnings

Amcon Distributing Q3 EPS $2.13 Down From $2.46 YoY, Sales $739.615M Up From $717.852M YoY

Multinational payment card services provider Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) continues to perform as a consistently reliable blue-chip enterprise. On a year-to-date basis, V stock has gained just over 10%, which is a modest but noticeable improvement over the benchmark S&amp;P 500 index. At the same time, broader economic concerns cloud the company, which is set to release its results for the <a href="https://www.benzinga.com/quote/V/earnings">fiscal third quarter</a> near month's end. Still, the unusual circumstances may present a bullish edge for speculators.
On July 29, Visa is scheduled to disclose its financial results, with Wall Street analysts anticipating earnings per share of $2.83 on revenue of $9.82 billion. In the year-ago quarter, the financial services giant posted earnings of $2.42 per share with a top-line print of $8.9 billion. What should boost confidence for investors is that Visa commands a long history of earnings beats.
That said, it's also interesting that the sole hiccup since the fiscal third quarter of 2020 materialized one year ago, when Visa suffered a slight miss against revenue expectations. Could lightning strike twice for the bears?
It's possible and the pessimists might argue that it's probable. Consumers have been <a href="https://www.benzinga.com/news/25/04/44916124/frozen-pizza-sales-surge-like-2009-recession-as-americans-cut-back-on-dining-out-amid-economic-strain">pivoting toward lower-cost food alternatives</a>, a dynamic that echoes the 2009 recession. Unfortunately for the company, broader headwinds have <a href="https://www.benzinga.com/quote/V">impacted its revenue streams</a>, suggesting that Visa is vulnerable to economic softness — despite the counterargument that credit cards can allow holders to stretch their finances.
Nevertheless, the <a href="https://www.benzinga.com/markets/large-cap/25/07/46365557/visa-vs-mastercard">broader transition toward digital payment solutions</a> has so far bolstered V stock. While there are consumers that still prefer to use cash, the emphasis today is on greater convenience and wider integration with digital platforms. Overall, the idea is that this massive tailwind can help Visa ride out the present economic turbulence.
<h2 class="wp-block-heading">Establishing The Benchmark For V Stock And Beating It</h2>
While the financial services provider has performed well this year, V stock has admittedly encountered a downdraft. Since June 11, the security has struggled within a bearish trend channel, raising legitimate questions about its forward trajectory. Still, the consolidation may be signaling for a possible reversal.
First, it's important to establish a baseline for V stock, which would be its null hypothesis: the expected performance of the security assuming no mispricing. Since January 2019, the chance that a one-week long position in Visa stock will be profitable is 56.43%. Therefore, an alternative hypothesis must be able to beat this benchmark.
In this case, our alternative hypothesis is that because V stock is printing a rare quantitative signal, the probability of upside is 78.57%.
To arrive at the above conclusion, you cannot simply look at the share price and make such a determination. Instead, we can discretize price action into market breadth, essentially converting it into sequences of accumulative and distributive sessions. In this manner, we're dealing with root demand; that is, at the end of the session, was the market a net buyer or net seller?
By compressing price discovery into simple up weeks and down weeks, we can more easily identify recurring patterns — and more importantly, the likelihood of transition from one sequence to another. Conducting this exercise for Visa stock across 10-week intervals gives us the following demand profile:
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>L10 Category</td>
<td>Sample Size</td>
<td>Up Probability</td>
<td>Baseline Probability</td>
<td>Median Return if Up</td>
</tr>
<tr>
<td>2-8-D</td>
<td>6</td>
<td>50.00%</td>
<td>56.30%</td>
<td>2.04%</td>
</tr>
<tr>
<td>3-7-D</td>
<td>20</td>
<td>55.00%</td>
<td>56.30%</td>
<td>3.29%</td>
</tr>
<tr>
<td>3-7-U</td>
<td>4</td>
<td>50.00%</td>
<td>56.30%</td>
<td>1.70%</td>
</tr>
<tr>
<td>4-6-D</td>
<td>38</td>
<td>47.37%</td>
<td>56.30%</td>
<td>3.37%</td>
</tr>
<tr>
<td>4-6-U</td>
<td>14</td>
<td>64.29%</td>
<td>56.30%</td>
<td>1.26%</td>
</tr>
<tr>
<td>5-5-D</td>
<td>32</td>
<td>50.00%</td>
<td>56.30%</td>
<td>2.80%</td>
</tr>
<tr>
<td>5-5-U</td>
<td>39</td>
<td>61.54%</td>
<td>56.30%</td>
<td>1.91%</td>
</tr>
<tr>
<td>6-4-D</td>
<td>13</td>
<td>76.92%</td>
<td>56.30%</td>
<td>1.69%</td>
</tr>
<tr>
<td>6-4-U</td>
<td>61</td>
<td>54.10%</td>
<td>56.30%</td>
<td>1.33%</td>
</tr>
<tr>
<td>7-3-U</td>
<td>61</td>
<td>55.74%</td>
<td>56.30%</td>
<td>1.43%</td>
</tr>
<tr>
<td>8-2-U</td>
<td>26</td>
<td>57.69%</td>
<td>56.30%</td>
<td>1.47%</td>
</tr>
<tr>
<td>9-1-U</td>
<td>5</td>
<td>20.00%</td>
<td>56.30%</td>
<td>4.96%</td>
</tr>
</tbody>
</table>
</figure>
In the trailing two months, V stock is printing a "6-4-D" sequence: four up weeks, six down weeks, with a negative trajectory across the 10-week period. It's a rare sequence, having materialized only 14 times since January 2019. However, the takeaway, again, is that in 76.92% of cases, the following week's price action results in upside, with a median return of 1.69%.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18151509/Visa-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-992129" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18151509/Visa-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18151509/Visa-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18151509/Visa-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18151509/Visa-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Assuming that V stock closes around $349, bullish speculators may anticipate a quick push to $354.90, possibly to $355 given the psychological importance. From here, if the bulls maintain control over the next four weeks, a push toward $361 is reasonable based on an analysis of past analogs.
<h2 class="wp-block-heading">Taking A Shot On Visa</h2>
Armed with the market intelligence above, there are two ways to play V stock. First, you may consider the 352.50/355 bull call spread expiring Aug. 1. This transaction involves buying the $352.50 call and simultaneously selling the $355 call, for a net debit paid of $125 (the most that can be lost in the trade). Should V rise through the short strike price ($355) at expiration, the maximum reward is also $125, a 100% payout.
With the above trade, you have the option of pulling out ahead of earnings if conditions justify it or wait till after the earnings disclosure.
Another idea to consider is the 355/360 bull spread expiring Aug. 15. This transaction requires a net debit of $215 at time of writing. However, if Visa stock manages to rise through the short strike price at expiration, the maximum reward is $285, a payout of roughly 133%.
Of course, the above trade hinges on the viability of the 6-4-D sequence and its projected statistical response. Running a one-tailed binomial test reveals a p-value of 7.76. This means that there's a 7.76% probability that V stock can rise 76.92% on a frequency basis by random chance rather than as a "consequence" of the 6-4-D sequence.
Scientifically, this does not meet the threshold of statistical significance, where the p-value cutoff is 5%. However, given the open-system nature of the stock market, this is unquestionably an empirically unusual quant signal — one that could provide an edge for adventurous speculators.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/07/46480506/wmt-stock-walmart-science-mispriced-options">Options Corner: Use Science To Take Advantage Of Walmart&#8217;s Mispriced Derivatives</a></li>
</ul>
Photo: Shutterstock

Equities

Long Ideas

Options

Options Corner: Visa Is Setting Up A Statistical Breakout That You Don't Want To Miss

HOOKIPA Pharma To Voluntarily Delist And Deregister

As previously disclosed, on February 18, 2025, Society Pass Incorporated (the "Company") received written notice (the "Delist Notice") from The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon the Company's continued non-compliance with Rule 5550(b)(2) which requires that the Company shall maintain at least $2,500,000 stockholders' equity (the "Equity Rule"), the Nasdaq staff determined to delist the Company's common stock from the Nasdaq Capital Market effective February 27, 2025 unless the Company timely requested an appeal of this determination before the Nasdaq Hearings Panel (the "Panel"). The Company timely requested a hearing (the "Hearing") before the Panel, which stayed the suspension of the Company's common stock pending the Panel's decision, and the Hearing was held on April 1, 2025. On April 9, 2025, the Panel issued a decision that granted the Company's request to continue its listing on Nasdaq based on the information presented. The Panel has determined to grant the Company's request for an exception until June 30, 2025. On July 15, 2025, the Panel issued an amended decision to further grant the Company's request for an exception until August 18, 2025. The compliance plan was conditioned on (i) the Company filing a Form 8-K describing the transactions undertaken by the Company to achieve compliance and demonstrate long-term compliance with the Equity Rule, and by providing an indication of its equity following those transactions; and (ii) the Company will evidence compliance with all applicable criteria for continued listing on the Nasdaq Capital Market.

SOPA

Society Pass Granted Nasdaq Extension Until August 18, 2025 To Regain Compliance

ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) today announced that it has applied to the Alberta Securities Commission (ASC), as principal regulator, and the Ontario Securities Commission (OSC) for a joint order (the Order Sought) to cease to be a reporting issuer in all jurisdictions of Canada in which it is a reporting issuer. If the Order Sought is granted by the ASC and the OSC, ConocoPhillips will cease to be a reporting issuer in any jurisdiction in Canada.
Notwithstanding a decision that ConocoPhillips is not a reporting issuer in Canada, ConocoPhillips will continue to file all financial statements and other continuous disclosure materials required to be filed by it in accordance with the applicable securities laws of the United States and the rules of the New York Stock Exchange (NYSE). All such continuous disclosure documents of ConocoPhillips are publicly available to all security holders of ConocoPhillips under ConocoPhillips' profile at <a href="https://www.sec.gov/">www.sec.gov</a>. ConocoPhillips' security holders residing in Canada will continue to receive copies of the continuous disclosure documents that are required to be delivered to security holders in the United States, in the same manner and at the same time as is required under the applicable securities laws of the United States and the rules of the NYSE.

ConocoPhillips Applies To Cease Canadian Reporting Issuer Status Through Joint ASC And OSC Order

Wall Street extended its historic rally this week, with major benchmarks such as the S&amp;P 500 and the tech-heavy Nasdaq 100 hitting fresh all-time highs, as strong corporate earnings, robust economic data and AI-fueled tech momentum continued <a href="https://www.benzinga.com/markets">to boost investor optimism.</a>
Big banks beat earnings estimates, setting a strong tone for the season. Airlines and consumer-focused giants also impressed.
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) reported their best trading weeks of the year, further supporting the confidence that solid consumer demand is driving margins across sectors.
Economic strength was underscored by June's retail sales data, which showed a 0.6% monthly increase — crushing economists&#8217; forecast of 0.1% — while jobless claims dropped to 221,000, their <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46467952/us-retail-sales-june-2025-fed-trump-inflation-consumer">lowest level since April.</a>
Investors appear to be buying into a &#8220;Goldilocks&#8221; scenario, where growth is strong enough to support profits but not so strong as to trigger new inflation fears. June's inflation data came in broadly lower than expected, marking a sharp turnaround from the stagflation concerns that gripped the market in the first quarter.
Since the post-tariff lows in April, the S&amp;P 500 has surged 27%, a rally that now ranks among the sharpest three-month advances ever.
Read also: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46426381/sp500-rally-investor-sentiment-2025">S&amp;P 500 Defies Odds With Rare Rally — But &#8216;Toppy&#8217; Sentiment Creeps In</a>
NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) remains the epicenter of the tech rally. Its shares have nearly doubled since April, driven by surging demand for AI chips from cloud giants like Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).
Nvidia's rally has helped lift the "Magnificent Seven" — including Microsoft Corp., Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com Inc., Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) — to a combined $18.5 trillion market cap, surpassing <a href="https://www.benzinga.com/markets/economic-data/25/07/46477275/wall-street-big-7-are-now-bigger-than-chinas-entire-economy">China's entire nominal GDP.</a>
Despite the economic strength, President Donald Trump has renewed his attacks on Fed Chair Jerome Powell, calling for immediate rate cuts. He even reportedly floated the idea of firing Powell before <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46454852/trump-fed-powell-odds-inflation-markets">backing off the proposal.</a>
Meanwhile, Fed Gov. Christopher Waller — a potential candidate to replace Powell next year — said he's willing to cut rates by <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46491573/waller-fed-chair-trump-rate-cut-july">the end of July.</a> The Fed meeting on July 30 now carries heightened political stakes, with growing signs of internal divisions.
Read Now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46496809/magnificent-7-stocks-wall-streets-estimates-google-alphabet-microsoft">These Two Magnificent 7 Stocks Are About To Hit Overdrive — And Wall Street&#8217;s Getting Excited </a></li>
</ul>
Photo: Shutterstock

Analyst Color

Government

Large Cap

Macro Economic Events

Regulations

Economics

Federal Reserve

Analyst Ratings

Tech

AAPL

AMZN

GOOGL

MSFT

NVDA

TSLA

Wall Street Sets New Records As Magnificent Seven Valuation Tops $18.5 Trillion: This Week In Markets

<a href="https://www.bloomberg.com/news/articles/2025-07-18/paramount-suitor-meets-with-fcc-chairman-seeking-ok-for-deal?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-18/paramount-suitor-meets-with-fcc-chairman-seeking-ok-for-deal?embedded-checkout=true</a>

PARA

'Paramount Suitor Meets With FCC Chairman, Seeking OK for Deal'- Bloomberg

<a href="https://www.wsj.com/politics/national-security/trump-ukraine-weapons-shipment-priority-be11f155" title="https://www.wsj.com/politics/national-security/trump-ukraine-weapons-shipment-priority-be11f155">https://www.wsj.com/politics/national-security/trump-ukraine-weapons-shipment-priority-be11f155</a>

Politics

Global

'U.S. Reorders Arms Deliveries to Free Up More Patriots for Ukraine' - WSJ Exclusive

Press Releases

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

Small Cap

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

RDHL

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Akanda

Artelo Biosciences

Biofrontera

CNS Pharma

China Pharma Holding

Enveric Biosciences

Evoke Pharma

Impact BioMedical

Jaguar Health

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

Talphera

TNF Pharmaceuticals

Traws Pharma

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

cbdMD

Screenshot 2025-02-25 at 7.29.32 PM

Biotech

RedHill Licenses RHB-102 Worldwide Excluding North America To Hyloris For Up To $60M In Potential Milestone Payments Plus Royalties

Screenshot 2025-02-04 at 6.43.58 PM

BAYRY

New Prostate Cancer Hope? Bayer-Funded Phase 2 Study To Test Combination Of RedHill&#39;s Opaganib And Bayer&#39;s Darolutamide, To Overcome Androgen Resistance

Screenshot 2024-12-05 at 6.50.09 PM

Supreme Court Of New York Awards RedHill Biopharma Approx. $8 Million Plus Costs In Breach Of Contract Lawsuit

Screenshot 2024-10-14 at 5.39.36 PM

RedHill Biopharma Secures U.S. Government Funding Through BARDA To Advance Opaganib For Ebola Treatment

Screenshot 2024-08-22 at 5.32.58 PM

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Comments

Redhill Biopharma

Actualités

Dernières nouvelles pour Redhill Biopharma (NASDAQ:RDHL) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL